Companies › FutureChem
2 active drug programs in 3 registered trials: 3 Phase 3; Oncology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [177-Lu]Ludotadipep Lutetium-177 labeled PSMA-targeting peptide radiopharmaceutical | – | Phase 3 | Prostate Cancer | Mar 2028 |
| [F-18]Florastamin Radiopharmaceutical PET/CT imaging agent | – | Phase 3 | High Risk Prostate Carcinoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05004285 | [F-18]Florastamin | Phase 3 | High Risk Prostate Carcinoma | Oncology | Jun 2025 |
| NCT05936658 | [F-18]Florastamin | Phase 3 | High Risk Prostate Carcinoma | Oncology | Jun 2025 |
| NCT07853209 | [177-Lu]Ludotadipep | Phase 3 | Prostate Cancer | Oncology | Mar 2028 |
No annotated target.
–
Curium US Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.